Filing Flows

Filing Flows › Companies › Lucid Diagnostics › Cash flow

Lucid Diagnostics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$11.3M in Q2 2026 · −$47.2M over twelve months

Operating cash flow−$11.3M
Capital spending−$21K
Free cash flow−$11.3M
Cash conversion cycle30 days

Analysis

In Q2 2026, Lucid Diagnostics generated −$11.3M of operating cash flow and spent $21K on capital projects, leaving free cash flow of −$11.3M. That is $744K less than in Q2 2025 (−$10.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$46.9M; the largest uses were operating cash flow ($46.9M), capital spending ($315K); besides operations, cash came from other financing ($49.4M), shares issued ($25K); the cash balance rose by $2.3M.

Operating cash flow was −$11.3M against net income of −$11.7M. The largest differences: stock-based pay +$1.7M, payables −$411K, receivables −$399K.

Its cash conversion cycle was 30 days (receivables 55 + inventory 30 − payables 55).

Free cash flow

Lucid Diagnostics: free cash flow by quarterLucid Diagnostics: free cash flow by quarter−$10.2MQ3 2024−$9.9MQ4 2024−$12.6MQ1 2025−$10.6MQ2 2025−$10.9MQ3 2025−$12.6MQ4 2025−$12.3MQ1 2026−$11.3MQ2 2026
Operating cash flow less capital spending.
Lucid Diagnostics: operating cash flow against capital spendingLucid Diagnostics: operating cash flow against capital spendingOperating cash flowCapital spending−$10.2M$0Q3 2024−$9.9M$0Q4 2024−$12.5M$93KQ1 2025−$10.5M$25KQ2 2025−$10.9M$0Q3 2025−$12.6M$0Q4 2025−$12.1M$215KQ1 2026−$11.3M$21KQ2 2026
Latest (Q2 2026): Operating cash flow −$11.3M, Capital spending $21K.

Capital allocation, year by year

Lucid Diagnostics: where the cash came from (up) and went (down), by fiscal yearLucid Diagnostics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$17.7MFY2021: Shares issued $70.0MFY2021: Capital spending −$862K$70.0MFY2021FY2022: Operating cash flow −$29.7MFY2022: Shares issued $2.5MFY2022: Capital spending −$3.2M$2.5MFY2022FY2023: Operating cash flow −$32.8MFY2023: Net borrowing $10.0MFY2023: Shares issued $18.6M$28.6MFY2023FY2024: Operating cash flow −$44.1MFY2024: Net borrowing $19.0MFY2024: Shares issued $29.8MFY2024: Capital spending −$296K$48.8MFY2024FY2025: Operating cash flow −$46.5MFY2025: Net borrowing $360KFY2025: Shares issued $17KFY2025: Capital spending −$197K$377KFY2025
Over these 5 years operating cash flow totalled −$171M; the largest uses were operating cash flow ($171M) and capital spending ($4.6M). Cash-flow statements as filed.

Where the cash came from and went

Lucid Diagnostics: sources (+) and uses (−) of cash, Q2 2026Lucid Diagnostics: sources (+) and uses (−) of cash, Q2 2026Other financing$16.8MOperating cash flow−$11.3MCash drawn (+) / kept (−)−$5.5MCapital spending−$21KShares issued$1K
Lucid Diagnostics: sources (+) and uses (−) of cash, TTM to Q2 2026Lucid Diagnostics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$49.4MOperating cash flow−$46.9MCash drawn (+) / kept (−)−$2.3MCapital spending−$315KShares issued$25K

From profit to cash

Lucid Diagnostics: net income to operating cash flow, Q2 2026Lucid Diagnostics: net income to operating cash flow, Q2 2026Net income−$11.7MDepreciation & amortization$224KStock-based pay$1.7MReceivables−$399KPayables−$411KAccrued liabilities$243KPrepaid and other assets$52KOperating cash flow−$11.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202655305530
Q1 202648235714
Q2 2025172948-3
Q1 202562460-30

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$11.3M−$21K—$1K−$5.5M−$11.3M
Q1 2026−$12.1M−$215K—$20K$6.8M−$12.3M
Q4 2025−$12.6M——$2K$12.6M−$12.6M
Q3 2025−$10.9M——$2K−$16.2M−$10.9M
Q2 2025−$10.5M−$25K—$10K−$5.9M−$10.6M
Q1 2025−$12.5M−$93K$360K$3K−$2.9M−$12.6M
Q4 2024−$9.9M———−$7.9M−$9.9M
Q3 2024−$10.2M———$10.4M−$10.2M

Lucid Diagnostics: income statement and cash flow

Lucid Diagnostics, Q2 2026: revenue $1.5M (+27% year over year), operating margin -868.5%. The chart follows the revenue to costs, profit and cash.

Lucid Diagnostics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.